Journal
CELLS
Volume 10, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/cells10071577
Keywords
ubiquitin-proteasome system (UPS); immunoproteasome (iP); proteasome inhibitors (PIs); hematopoiesis; hematologic malignancies
Categories
Funding
- Wilhelm-Sander-Stiftung [2019.001.1]
- German Research Council (DFG) [HE6233/8-1, SFBTR186 A13]
- Comprehensive Cancer Center Mecklenburg-Vorpommern (CCC-MV)
- DFG (German Research Foundation) [393148499]
- Open Access Publication Fund of the University of Greifswald
Ask authors/readers for more resources
The ubiquitin-proteasome system (UPS) plays a crucial role in maintaining protein homeostasis, with inhibitors of the immunoproteasome showing potential as a targeted therapy for hematologic malignancies.
The ubiquitin-proteasome system (UPS) is a central part of protein homeostasis, degrading not only misfolded or oxidized proteins but also proteins with essential functions. The fact that a healthy hematopoietic system relies on the regulation of protein homeostasis and that alterations in the UPS can lead to malignant transformation makes the UPS an attractive therapeutic target for the treatment of hematologic malignancies. Herein, inhibitors of the proteasome, the last and most important component of the UPS enzymatic cascade, have been approved for the treatment of these malignancies. However, their use has been associated with side effects, drug resistance, and relapse. Inhibitors of the immunoproteasome, a proteasomal variant constitutively expressed in the cells of hematopoietic origin, could potentially overcome the encountered problems of non-selective proteasome inhibition. Immunoproteasome inhibitors have demonstrated their efficacy and safety against inflammatory and autoimmune diseases, even though their development for the treatment of hematologic malignancies is still in the early phases. Various immunoproteasome inhibitors have shown promising preliminary results in pre-clinical studies, and one inhibitor is currently being investigated in clinical trials for the treatment of multiple myeloma. Here, we will review data on immunoproteasome function and inhibition in hematopoietic cells and hematologic cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available